<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04202497</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-418-0004</org_study_id>
    <secondary_id>U1111-1242-8485</secondary_id>
    <nct_id>NCT04202497</nct_id>
  </id_info>
  <brief_title>A Study With [18F]MNI-1054 to Determine Lysine -Specific Demethylase 1A (LSD1) Brain Enzyme Occupancy of TAK-418 After Single-Dose Oral Administration in Healthy Participants</brief_title>
  <official_title>A Phase 1, Open-label, Positron Emission Tomography Study With [18F]MNI-1054 to Determine Lysine-Specific Demethylase 1A Brain Enzyme Occupancy of TAK-418 After Single-Dose Oral Administration in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine brain LSD1 enzyme occupancy and the relationship of&#xD;
      occupancy to TAK-418 dose and plasma exposure after single oral dosing of TAK-418 in healthy&#xD;
      participants using [18F]MNI-1054 positron emission tomography (PET) imaging.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study is called TAK-418. TAK-418 is being tested to determine&#xD;
      the relationship between brain LSD1 enzyme occupancy and TAK-418 plasma concentration. This&#xD;
      study will utilize the PET radiotracer [18F]MNI-1054 to evaluate the brain LSD1 enzyme&#xD;
      occupancy of TAK-418 after single dose oral administration in healthy adult participants.&#xD;
&#xD;
      The study will enroll approximately 16 participants. The TAK-418 starting dose is 1.5 mg,&#xD;
      given on Day 1. Each participant will receive one dose of TAK-418 and up to 3 dynamic&#xD;
      [18F]MNI-1054 PET scans to assess enzyme occupancy on baseline, Day 1 and Day 2 or 3&#xD;
      post-TAK-418 dosing.&#xD;
&#xD;
      This single center trial will be conducted in the United States. The overall time to&#xD;
      participate in this study is 62 days. Participants will be followed up on Day 14 for&#xD;
      follow-up safety assessments.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study was prematurely terminated because of administrative reasons.&#xD;
  </why_stopped>
  <start_date type="Actual">December 18, 2019</start_date>
  <completion_date type="Actual">March 19, 2020</completion_date>
  <primary_completion_date type="Actual">March 5, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantitative Estimates of Binding of [18F]MNI-1054 Based on PET Radiotracer Kinetic Models At Baseline Scan on Day -1</measure>
    <time_frame>Day -1</time_frame>
    <description>Enzyme binding parameter [Ki] was obtained from irreversible 2-tissue compartment model (mL/cm^3/min). Data is reported for the following brain regions: cerebellum, frontal lobe, hippocampus, occipital Lobe, pons, and striatum. Here, mL/cm^3/min signifies 'milliliter per cubic centimeter per minute'.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantitative Estimates of Binding of [18F]MNI-1054 Based on PET Radiotracer Kinetic Models on Day 1</measure>
    <time_frame>Day 1</time_frame>
    <description>Enzyme binding parameter [Ki] was obtained from irreversible 2-tissue compartment model (mL/cm^3/min). Data is reported for the following brain regions: cerebellum, frontal lobe, hippocampus, occipital Lobe, pons, and striatum. Here, mL/cm^3/min signifies 'milliliter per cubic centimeter per minute'.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantitative Estimates of Binding of [18F]MNI-1054 Based on PET Radiotracer Kinetic Models on Day 2</measure>
    <time_frame>Day 2</time_frame>
    <description>Enzyme binding parameter [Ki] was obtained from irreversible 2-tissue compartment model (mL/cm^3/min). Data is reported for the following brain regions: cerebellum, frontal lobe, hippocampus, occipital Lobe, pons, and striatum. Here, mL/cm^3/min signifies 'milliliter per cubic centimeter per minute'.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Enzyme Occupancy Based on Quantitative Estimates of Binding for TAK-418 on Day 1</measure>
    <time_frame>Day 1</time_frame>
    <description>Lysine-Specific Demethylase 1A (LSD1) enzyme occupancy (%) in region of interest (ROI) after a single dose of TAK-418 was obtained from the baseline and postdose Ki values as follows: occupancy (1st postdose) = 100*(Ki [baseline] - Ki [1st postdose]) / Ki (baseline). Data is reported for following brain regions: cerebellum, frontal lobe, hippocampus, occipital Lobe, pons, and striatum.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Enzyme Occupancy Based on Quantitative Estimates of Binding for TAK-418 on Day 2</measure>
    <time_frame>Day 2</time_frame>
    <description>LSD1 enzyme occupancy (%) in ROI after a single dose of TAK-418 was obtained from the baseline and postdose Ki values as follows: occupancy (2nd postdose) = 100*(Ki [baseline] - Ki [2nd postdose]) / Ki (baseline). Data is reported for following brain regions: cerebellum, frontal lobe, hippocampus, occipital Lobe, pons, and striatum.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration for TAK-418</measure>
    <time_frame>Day 1: pre-dose and at multiple time points (up to 3 hours) post-dose, immediately before and after the Day 1 PET scan, and within 30 minutes before and 30 minutes after Day 2 or 3 PET scan</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast: Area Under the Plasma Concentration-time Curve (AUC) From Time 0 to Time of the Last Quantifiable Concentration for TAK-418</measure>
    <time_frame>Day 1: pre-dose and at multiple time points (up to 3 hours) post-dose, immediately before and after the Day 1 PET scan, and within 30 minutes before and 30 minutes after Day 2 or 3 PET scan</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCâˆž: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-418</measure>
    <time_frame>Day 1: pre-dose and at multiple time points (up to 3 hours) post-dose, immediately before and after the Day 1 PET scan, and within 30 minutes before and 30 minutes after Day 2 or 3 PET scan</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ED50 PET Enzyme Occupancy</measure>
    <time_frame>Days 1 to 2</time_frame>
    <description>The relationship between PET enzyme occupancy and TAK-418 dose level was investigated using an Emax model containing the regression parameters maximal target occupancy (Emax) and dose that gives 50 percent (%) of Emax (ED50). ED50 values are reported for following brain regions: cerebellum, frontal lobe, hippocampus, occipital Lobe, pons, and striatum. The data tabulated are the estimated value and confidence intervals of the ED50 value derived from an Emax model fit across all data points from all arms. ED50 is the dose at which 50% enzyme occupancy is expected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting One or More Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>From first dose of [18F]MNI-1054 radiotracer injection up to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Abnormal Laboratory Values</measure>
    <time_frame>From first dose of [18F]MNI-1054 radiotracer injection up to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Abnormal Vital Signs</measure>
    <time_frame>From first dose of [18F]MNI-1054 radiotracer injection up to Day 14</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>TAK-418 1.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-418 1.5 milligram (mg), orally, once on Day 1. Participants will also receive 10 millicurie (mCi) of [18F]MNI-1054 injection intravenously, prior to each PET scans on Day -1, Day 1, and either on Day 2 or 3. Dose levels for subsequent participants may vary based on available review of imaging and pharmacokinetics (PK) data.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-418</intervention_name>
    <description>TAK-418 orally.</description>
    <arm_group_label>TAK-418 1.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]MNI-1054 (radiotracer)</intervention_name>
    <description>[18F]MNI-1054 injection.</description>
    <arm_group_label>TAK-418 1.5 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The participant must have a body mass index (BMI) greater than or equal to (&gt;=) 18.5&#xD;
             and less than or equal to (&lt;=) 30.0 kilogram per square meter (kg/m^2) at the&#xD;
             screening visit.&#xD;
&#xD;
          2. The participant must be a current nonsmoker at screening as demonstrated by negative&#xD;
             cotinine test.&#xD;
&#xD;
          3. The participant has adequate circulation to both hands for safe placement of arterial&#xD;
             lines (as determined by Allen's test).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has a known hypersensitivity to any component of the formulation of TAK-418 or related&#xD;
             compounds, including [18F]MNI-1054.&#xD;
&#xD;
          2. The participant has a positive alcohol or drug screen.&#xD;
&#xD;
          3. The participant has a history of alcohol consumption exceeding 2 standard drinks per&#xD;
             day on average (1 glass is approximately equivalent to the following: beer [354&#xD;
             milliliter (mL)/12 ounce (oz)], wine [118 mL/4 oz], or distilled spirits [29.5 mL/1&#xD;
             oz] per day).&#xD;
&#xD;
          4. The participant consumes excessive amounts, defined as greater than 6 servings (1&#xD;
             serving is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola,&#xD;
             energy drinks, or other caffeinated beverages per day.&#xD;
&#xD;
          5. The participant has a substance abuse disorder.&#xD;
&#xD;
          6. The participant cannot tolerate venipuncture or has poor venous access that would&#xD;
             cause difficulty in collecting blood samples.&#xD;
&#xD;
          7. The participant has contraindications to undergoing magnetic resonance imaging (MRI)&#xD;
             examination including but not limited to implants, such as implanted cardiac&#xD;
             pacemakers or defibrillators, insulin pumps, cochlear implants, metallic ocular&#xD;
             foreign body, implanted neural stimulators, central nervous system aneurysm clips, and&#xD;
             other medical implants that have not been certified for MRI, or history of&#xD;
             claustrophobia in MRI.&#xD;
&#xD;
          8. The participant has clinically significant abnormal findings on brain MRI scan that in&#xD;
             the opinion of the investigator may interfere with the interpretation of the PET&#xD;
             imaging.&#xD;
&#xD;
          9. The participant has experienced an acute illness within 10 days before the screening&#xD;
             visit.&#xD;
&#xD;
         10. The participant has a risk of suicide according to the investigator's clinical&#xD;
             judgement per the Columbia-Suicide Severity Rating Scale at screening or has made a&#xD;
             suicide attempt in the 12 months before screening.&#xD;
&#xD;
         11. The participant has luteinizing hormone, follicle stimulating hormone (FSH), or&#xD;
             estradiol levels that are clinically abnormal.&#xD;
&#xD;
         12. The participant has existing skin rashes that can be diagnosed as dermatitis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Invicro, A Konica Minolta Company</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 12, 2019</study_first_submitted>
  <study_first_submitted_qc>December 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2019</study_first_posted>
  <results_first_submitted>March 16, 2021</results_first_submitted>
  <results_first_submitted_qc>July 9, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 30, 2021</results_first_posted>
  <last_update_submitted>July 9, 2021</last_update_submitted>
  <last_update_submitted_qc>July 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Therapy</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/takeda/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 5, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/97/NCT04202497/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 19, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/97/NCT04202497/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 1 investigative site in the United States from 18 December 2019 to 19 March 2020.</recruitment_details>
      <pre_assignment_details>Healthy participants were enrolled in this study to receive up to 10 millicurie [mCi]) of [18F]MNI-1054 for 1 positron emission tomography (PET) Scan on Day -1 (Baseline Scan), and then eligible participants entered into 1 of 3 treatment groups in the Treatment Period to receive 10 mCi of [18F]MNI-1054 for 2 PET scans after single dose of TAK-418 1.5 milligram (mg), 10 mg, or 30 mg on Day 1 and either Day 2 or 3. Study was prematurely terminated because of administrative reasons.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Baseline [18F]MNI-1054</title>
          <description>[18F]MNI-1054 up to 10 mCi, PET radiotracer injection, intravenously, prior to PET scan on Day -1 (Baseline scan).</description>
        </group>
        <group group_id="P2">
          <title>TAK-418 1.5 mg</title>
          <description>TAK-418 1.5 mg, capsule, orally, once on Day 1 and up to 10 mCi of [18F]MNI-1054 PET radiotracer injection, intravenously, prior to each PET scans on Day 1, and either on Day 2 or 3 post-TAK-418 dose in the Treatment Period. All participants received [18F]MNI-1054 up to 10 mCi, injection, intravenously, prior to PET scan on Day -1 (Baseline scan).</description>
        </group>
        <group group_id="P3">
          <title>TAK-418 10 mg</title>
          <description>TAK-418 10 mg, capsule, orally, once on Day 1 and up to 10 mCi of [18F]MNI-1054 PET radiotracer injection, intravenously, prior to each PET scans on Day 1, and either on Day 2 or 3 post-TAK-418 dose in the Treatment Period. All participants received [18F]MNI-1054 up to 10 mCi, injection, intravenously, prior to PET scan on Day -1 (Baseline scan).</description>
        </group>
        <group group_id="P4">
          <title>TAK-418 30 mg</title>
          <description>TAK-418 30 mg, capsule, orally, once on Day 1 and up to 10 mCi of [18F]MNI-1054 PET radiotracer injection, intravenously, prior to each PET scans on Day 1, and either on Day 2 or 3 post-TAK-418 dose in the Treatment Period. All participants received [18F]MNI-1054 up to 10 mCi, injection, intravenously, prior to PET scan on Day -1 (Baseline scan).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Baseline Scan (Day-1)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Metabolites of [18F]MNI-1054 could not be analyzed</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period (Day 1 Through Day 2-3)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2">Eligible participants from Baseline Period who received 10 mCi of [18F]MNI-1054 on Day -1.</participants>
                <participants group_id="P3" count="2">Eligible participants from Baseline Period who received 10 mCi of [18F]MNI-1054 on Day -1.</participants>
                <participants group_id="P4" count="2">Eligible participants from Baseline Period who received 10 mCi of [18F]MNI-1054 on Day -1.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The safety set included all enrolled participants who received at least 1 dose of [18F]MNI-1054 or TAK-418.</population>
      <group_list>
        <group group_id="B1">
          <title>Baseline [18F]MNI-1054</title>
          <description>[18F]MNI-1054 up to 10 mCi, PET radiotracer injection, intravenously, prior to PET scan on Day -1 (Baseline scan).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.7" spread="8.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kilogram per square meter (kg/m^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.81" spread="2.594"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Quantitative Estimates of Binding of [18F]MNI-1054 Based on PET Radiotracer Kinetic Models At Baseline Scan on Day -1</title>
        <description>Enzyme binding parameter [Ki] was obtained from irreversible 2-tissue compartment model (mL/cm^3/min). Data is reported for the following brain regions: cerebellum, frontal lobe, hippocampus, occipital Lobe, pons, and striatum. Here, mL/cm^3/min signifies 'milliliter per cubic centimeter per minute'.</description>
        <time_frame>Day -1</time_frame>
        <population>The pharmacodynamics (PD) set included all participants who received TAK-418 and have at least 1 analyzable PET Scan following TAK-418.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-418 1.5 mg</title>
            <description>TAK-418 1.5 mg, capsule, orally, once on Day 1 and up to 10 mCi of [18F]MNI-1054 PET radiotracer injection, intravenously, prior to each PET scans on Day 1, and either on Day 2 or 3 post-TAK-418 dose in the Treatment Period. All participants received [18F]MNI-1054 up to 10 mCi, injection, intravenously, prior to PET scan on Day -1 (Baseline scan).</description>
          </group>
          <group group_id="O2">
            <title>TAK-418 10 mg</title>
            <description>TAK-418 10 mg, capsule, orally, once on Day 1 and up to 10 mCi of [18F]MNI-1054 PET radiotracer injection, intravenously, prior to each PET scans on Day 1, and either on Day 2 or 3 post-TAK-418 dose in the Treatment Period. All participants received [18F]MNI-1054 up to 10 mCi, injection, intravenously, prior to PET scan on Day -1 (Baseline scan).</description>
          </group>
          <group group_id="O3">
            <title>TAK-418 30 mg</title>
            <description>TAK-418 30 mg, capsule, orally, once on Day 1 and up to 10 mCi of [18F]MNI-1054 PET radiotracer injection, intravenously, prior to each PET scans on Day 1, and either on Day 2 or 3 post-TAK-418 dose in the Treatment Period. All participants received [18F]MNI-1054 up to 10 mCi, injection, intravenously, prior to PET scan on Day -1 (Baseline scan).</description>
          </group>
        </group_list>
        <measure>
          <title>Quantitative Estimates of Binding of [18F]MNI-1054 Based on PET Radiotracer Kinetic Models At Baseline Scan on Day -1</title>
          <description>Enzyme binding parameter [Ki] was obtained from irreversible 2-tissue compartment model (mL/cm^3/min). Data is reported for the following brain regions: cerebellum, frontal lobe, hippocampus, occipital Lobe, pons, and striatum. Here, mL/cm^3/min signifies 'milliliter per cubic centimeter per minute'.</description>
          <population>The pharmacodynamics (PD) set included all participants who received TAK-418 and have at least 1 analyzable PET Scan following TAK-418.</population>
          <units>mL/cm^3/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cerebellum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03405" spread="0.002192"/>
                    <measurement group_id="O2" value="0.03515" spread="0.005869"/>
                    <measurement group_id="O3" value="0.03560" spread="0.003394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Frontal Lobe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01930" spread="0.004525"/>
                    <measurement group_id="O2" value="0.02070" spread="0.004384"/>
                    <measurement group_id="O3" value="0.02140" spread="0.002263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hippocampus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01900" spread="0.000141"/>
                    <measurement group_id="O2" value="0.01935" spread="0.005303"/>
                    <measurement group_id="O3" value="0.01960" spread="0.001414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occipital Lobe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02140" spread="0.002404"/>
                    <measurement group_id="O2" value="0.02225" spread="0.003606"/>
                    <measurement group_id="O3" value="0.02365" spread="0.002616"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pons</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01685" spread="0.000071"/>
                    <measurement group_id="O2" value="0.01855" spread="0.004313"/>
                    <measurement group_id="O3" value="0.01870" spread="0.004667"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Striatum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01575" spread="0.004031"/>
                    <measurement group_id="O2" value="0.01930" spread="0.004950"/>
                    <measurement group_id="O3" value="0.01995" spread="0.003323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Quantitative Estimates of Binding of [18F]MNI-1054 Based on PET Radiotracer Kinetic Models on Day 1</title>
        <description>Enzyme binding parameter [Ki] was obtained from irreversible 2-tissue compartment model (mL/cm^3/min). Data is reported for the following brain regions: cerebellum, frontal lobe, hippocampus, occipital Lobe, pons, and striatum. Here, mL/cm^3/min signifies 'milliliter per cubic centimeter per minute'.</description>
        <time_frame>Day 1</time_frame>
        <population>The PD set included all participants who received TAK-418 and have at least 1 analyzable PET Scan following TAK-418.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-418 1.5 mg</title>
            <description>TAK-418 1.5 mg, capsule, orally, once on Day 1 and up to 10 mCi of [18F]MNI-1054 PET radiotracer injection, intravenously, prior to each PET scans on Day 1, and either on Day 2 or 3 post-TAK-418 dose in the Treatment Period. All participants received [18F]MNI-1054 up to 10 mCi, injection, intravenously, prior to PET scan on Day -1 (Baseline scan).</description>
          </group>
          <group group_id="O2">
            <title>TAK-418 10 mg</title>
            <description>TAK-418 10 mg, capsule, orally, once on Day 1 and up to 10 mCi of [18F]MNI-1054 PET radiotracer injection, intravenously, prior to each PET scans on Day 1, and either on Day 2 or 3 post-TAK-418 dose in the Treatment Period. All participants received [18F]MNI-1054 up to 10 mCi, injection, intravenously, prior to PET scan on Day -1 (Baseline scan).</description>
          </group>
          <group group_id="O3">
            <title>TAK-418 30 mg</title>
            <description>TAK-418 30 mg, capsule, orally, once on Day 1 and up to 10 mCi of [18F]MNI-1054 PET radiotracer injection, intravenously, prior to each PET scans on Day 1, and either on Day 2 or 3 post-TAK-418 dose in the Treatment Period. All participants received [18F]MNI-1054 up to 10 mCi, injection, intravenously, prior to PET scan on Day -1 (Baseline scan).</description>
          </group>
        </group_list>
        <measure>
          <title>Quantitative Estimates of Binding of [18F]MNI-1054 Based on PET Radiotracer Kinetic Models on Day 1</title>
          <description>Enzyme binding parameter [Ki] was obtained from irreversible 2-tissue compartment model (mL/cm^3/min). Data is reported for the following brain regions: cerebellum, frontal lobe, hippocampus, occipital Lobe, pons, and striatum. Here, mL/cm^3/min signifies 'milliliter per cubic centimeter per minute'.</description>
          <population>The PD set included all participants who received TAK-418 and have at least 1 analyzable PET Scan following TAK-418.</population>
          <units>mL/cm^3/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cerebellum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01020" spread="0.003536"/>
                    <measurement group_id="O2" value="0.00405" spread="0.000495"/>
                    <measurement group_id="O3" value="0.00760" spread="0.000849"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Frontal Lobe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01295" spread="0.001768"/>
                    <measurement group_id="O2" value="0.00980" spread="0.001697"/>
                    <measurement group_id="O3" value="0.01435" spread="0.002333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hippocampus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01260" spread="0.000990"/>
                    <measurement group_id="O2" value="0.00635" spread="0.004031"/>
                    <measurement group_id="O3" value="0.01240" spread="0.000000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occipital Lobe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01245" spread="0.002758"/>
                    <measurement group_id="O2" value="0.00910" spread="0.000990"/>
                    <measurement group_id="O3" value="0.01430" spread="0.001556"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pons</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01265" spread="0.006718"/>
                    <measurement group_id="O2" value="0.00970" spread="0.000707"/>
                    <measurement group_id="O3" value="0.01515" spread="0.000212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Striatum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01185" spread="0.002192"/>
                    <measurement group_id="O2" value="0.00785" spread="0.000495"/>
                    <measurement group_id="O3" value="0.01365" spread="0.000071"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Quantitative Estimates of Binding of [18F]MNI-1054 Based on PET Radiotracer Kinetic Models on Day 2</title>
        <description>Enzyme binding parameter [Ki] was obtained from irreversible 2-tissue compartment model (mL/cm^3/min). Data is reported for the following brain regions: cerebellum, frontal lobe, hippocampus, occipital Lobe, pons, and striatum. Here, mL/cm^3/min signifies 'milliliter per cubic centimeter per minute'.</description>
        <time_frame>Day 2</time_frame>
        <population>The PD set included all participants who received TAK-418 and have at least 1 analyzable PET Scan following TAK-418.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-418 1.5 mg</title>
            <description>TAK-418 1.5 mg, capsule, orally, once on Day 1 and up to 10 mCi of [18F]MNI-1054 PET radiotracer injection, intravenously, prior to each PET scans on Day 1, and either on Day 2 or 3 post-TAK-418 dose in the Treatment Period. All participants received [18F]MNI-1054 up to 10 mCi, injection, intravenously, prior to PET scan on Day -1 (Baseline scan).</description>
          </group>
          <group group_id="O2">
            <title>TAK-418 10 mg</title>
            <description>TAK-418 10 mg, capsule, orally, once on Day 1 and up to 10 mCi of [18F]MNI-1054 PET radiotracer injection, intravenously, prior to each PET scans on Day 1, and either on Day 2 or 3 post-TAK-418 dose in the Treatment Period. All participants received [18F]MNI-1054 up to 10 mCi, injection, intravenously, prior to PET scan on Day -1 (Baseline scan).</description>
          </group>
          <group group_id="O3">
            <title>TAK-418 30 mg</title>
            <description>TAK-418 30 mg, capsule, orally, once on Day 1 and up to 10 mCi of [18F]MNI-1054 PET radiotracer injection, intravenously, prior to each PET scans on Day 1, and either on Day 2 or 3 post-TAK-418 dose in the Treatment Period. All participants received [18F]MNI-1054 up to 10 mCi, injection, intravenously, prior to PET scan on Day -1 (Baseline scan).</description>
          </group>
        </group_list>
        <measure>
          <title>Quantitative Estimates of Binding of [18F]MNI-1054 Based on PET Radiotracer Kinetic Models on Day 2</title>
          <description>Enzyme binding parameter [Ki] was obtained from irreversible 2-tissue compartment model (mL/cm^3/min). Data is reported for the following brain regions: cerebellum, frontal lobe, hippocampus, occipital Lobe, pons, and striatum. Here, mL/cm^3/min signifies 'milliliter per cubic centimeter per minute'.</description>
          <population>The PD set included all participants who received TAK-418 and have at least 1 analyzable PET Scan following TAK-418.</population>
          <units>mL/cm^3/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cerebellum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01865" spread="0.004455"/>
                    <measurement group_id="O2" value="0.00875" spread="0.001485"/>
                    <measurement group_id="O3" value="0.00690" spread="0.000566"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Frontal Lobe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01610" spread="0.003111"/>
                    <measurement group_id="O2" value="0.01020" spread="0.001838"/>
                    <measurement group_id="O3" value="0.01130" spread="0.002404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hippocampus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01650" spread="0.003960"/>
                    <measurement group_id="O2" value="0.00865" spread="0.001061"/>
                    <measurement group_id="O3" value="0.01015" spread="0.000919"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occipital Lobe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01665" spread="0.003889"/>
                    <measurement group_id="O2" value="0.01045" spread="0.002192"/>
                    <measurement group_id="O3" value="0.01180" spread="0.001980"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pons</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01265" spread="0.004738"/>
                    <measurement group_id="O2" value="0.01045" spread="0.002475"/>
                    <measurement group_id="O3" value="0.00985" spread="0.000636"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Striatum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01410" spread="0.004667"/>
                    <measurement group_id="O2" value="0.00915" spread="0.003182"/>
                    <measurement group_id="O3" value="0.00965" spread="0.001344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Enzyme Occupancy Based on Quantitative Estimates of Binding for TAK-418 on Day 1</title>
        <description>Lysine-Specific Demethylase 1A (LSD1) enzyme occupancy (%) in region of interest (ROI) after a single dose of TAK-418 was obtained from the baseline and postdose Ki values as follows: occupancy (1st postdose) = 100*(Ki [baseline] - Ki [1st postdose]) / Ki (baseline). Data is reported for following brain regions: cerebellum, frontal lobe, hippocampus, occipital Lobe, pons, and striatum.</description>
        <time_frame>Day 1</time_frame>
        <population>The PD set included all participants who received TAK-418 and have at least 1 analyzable PET Scan following TAK-418.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-418 1.5 mg</title>
            <description>TAK-418 1.5 mg, capsule, orally, once on Day 1 and up to 10 mCi of [18F]MNI-1054 PET radiotracer injection, intravenously, prior to each PET scans on Day 1, and either on Day 2 or 3 post-TAK-418 dose in the Treatment Period. All participants received [18F]MNI-1054 up to 10 mCi, injection, intravenously, prior to PET scan on Day -1 (Baseline scan).</description>
          </group>
          <group group_id="O2">
            <title>TAK-418 10 mg</title>
            <description>TAK-418 10 mg, capsule, orally, once on Day 1 and up to 10 mCi of [18F]MNI-1054 PET radiotracer injection, intravenously, prior to each PET scans on Day 1, and either on Day 2 or 3 post-TAK-418 dose in the Treatment Period. All participants received [18F]MNI-1054 up to 10 mCi, injection, intravenously, prior to PET scan on Day -1 (Baseline scan).</description>
          </group>
          <group group_id="O3">
            <title>TAK-418 30 mg</title>
            <description>TAK-418 30 mg, capsule, orally, once on Day 1 and up to 10 mCi of [18F]MNI-1054 PET radiotracer injection, intravenously, prior to each PET scans on Day 1, and either on Day 2 or 3 post-TAK-418 dose in the Treatment Period. All participants received [18F]MNI-1054 up to 10 mCi, injection, intravenously, prior to PET scan on Day -1 (Baseline scan).</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Enzyme Occupancy Based on Quantitative Estimates of Binding for TAK-418 on Day 1</title>
          <description>Lysine-Specific Demethylase 1A (LSD1) enzyme occupancy (%) in region of interest (ROI) after a single dose of TAK-418 was obtained from the baseline and postdose Ki values as follows: occupancy (1st postdose) = 100*(Ki [baseline] - Ki [1st postdose]) / Ki (baseline). Data is reported for following brain regions: cerebellum, frontal lobe, hippocampus, occipital Lobe, pons, and striatum.</description>
          <population>The PD set included all participants who received TAK-418 and have at least 1 analyzable PET Scan following TAK-418.</population>
          <units>percentage of occupancy</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cerebellum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.5" spread="10.61"/>
                    <measurement group_id="O2" value="87.0" spread="1.41"/>
                    <measurement group_id="O3" value="79.5" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Frontal Lobe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5" spread="10.61"/>
                    <measurement group_id="O2" value="44.0" spread="9.90"/>
                    <measurement group_id="O3" value="38.0" spread="9.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hippocampus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.0" spread="5.66"/>
                    <measurement group_id="O2" value="59.5" spread="26.16"/>
                    <measurement group_id="O3" value="40.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occipital Lobe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.0" spread="14.14"/>
                    <measurement group_id="O2" value="54.5" spread="4.95"/>
                    <measurement group_id="O3" value="43.5" spread="6.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pons</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" spread="39.60"/>
                    <measurement group_id="O2" value="37.5" spread="4.95"/>
                    <measurement group_id="O3" value="31.0" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Striatum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="16.97"/>
                    <measurement group_id="O2" value="50.5" spread="3.54"/>
                    <measurement group_id="O3" value="39.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Enzyme Occupancy Based on Quantitative Estimates of Binding for TAK-418 on Day 2</title>
        <description>LSD1 enzyme occupancy (%) in ROI after a single dose of TAK-418 was obtained from the baseline and postdose Ki values as follows: occupancy (2nd postdose) = 100*(Ki [baseline] - Ki [2nd postdose]) / Ki (baseline). Data is reported for following brain regions: cerebellum, frontal lobe, hippocampus, occipital Lobe, pons, and striatum.</description>
        <time_frame>Day 2</time_frame>
        <population>The PD set included all participants who received TAK-418 and have at least 1 analyzable PET Scan following TAK-418.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-418 1.5 mg</title>
            <description>TAK-418 1.5 mg, capsule, orally, once on Day 1 and up to 10 mCi of [18F]MNI-1054 PET radiotracer injection, intravenously, prior to each PET scans on Day 1, and either on Day 2 or 3 post-TAK-418 dose in the Treatment Period. All participants received [18F]MNI-1054 up to 10 mCi, injection, intravenously, prior to PET scan on Day -1 (Baseline scan).</description>
          </group>
          <group group_id="O2">
            <title>TAK-418 10 mg</title>
            <description>TAK-418 10 mg, capsule, orally, once on Day 1 and up to 10 mCi of [18F]MNI-1054 PET radiotracer injection, intravenously, prior to each PET scans on Day 1, and either on Day 2 or 3 post-TAK-418 dose in the Treatment Period. All participants received [18F]MNI-1054 up to 10 mCi, injection, intravenously, prior to PET scan on Day -1 (Baseline scan).</description>
          </group>
          <group group_id="O3">
            <title>TAK-418 30 mg</title>
            <description>TAK-418 30 mg, capsule, orally, once on Day 1 and up to 10 mCi of [18F]MNI-1054 PET radiotracer injection, intravenously, prior to each PET scans on Day 1, and either on Day 2 or 3 post-TAK-418 dose in the Treatment Period. All participants received [18F]MNI-1054 up to 10 mCi, injection, intravenously, prior to PET scan on Day -1 (Baseline scan).</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Enzyme Occupancy Based on Quantitative Estimates of Binding for TAK-418 on Day 2</title>
          <description>LSD1 enzyme occupancy (%) in ROI after a single dose of TAK-418 was obtained from the baseline and postdose Ki values as follows: occupancy (2nd postdose) = 100*(Ki [baseline] - Ki [2nd postdose]) / Ki (baseline). Data is reported for following brain regions: cerebellum, frontal lobe, hippocampus, occipital Lobe, pons, and striatum.</description>
          <population>The PD set included all participants who received TAK-418 and have at least 1 analyzable PET Scan following TAK-418.</population>
          <units>percentage of occupancy</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cerebellum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.5" spread="13.44"/>
                    <measurement group_id="O2" value="71.5" spread="4.95"/>
                    <measurement group_id="O3" value="82.0" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Frontal Lobe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="19.09"/>
                    <measurement group_id="O2" value="42.0" spread="9.90"/>
                    <measurement group_id="O3" value="51.0" spread="9.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hippocampus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" spread="21.21"/>
                    <measurement group_id="O2" value="44.5" spread="6.36"/>
                    <measurement group_id="O3" value="50.5" spread="4.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occipital Lobe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" spread="19.80"/>
                    <measurement group_id="O2" value="47.0" spread="11.31"/>
                    <measurement group_id="O3" value="53.5" spread="7.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pons</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" spread="28.28"/>
                    <measurement group_id="O2" value="32.5" spread="16.26"/>
                    <measurement group_id="O3" value="55.0" spread="2.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Striatum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.0" spread="35.36"/>
                    <measurement group_id="O2" value="42.0" spread="19.80"/>
                    <measurement group_id="O3" value="56.5" spread="6.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax: Maximum Observed Plasma Concentration for TAK-418</title>
        <time_frame>Day 1: pre-dose and at multiple time points (up to 3 hours) post-dose, immediately before and after the Day 1 PET scan, and within 30 minutes before and 30 minutes after Day 2 or 3 PET scan</time_frame>
        <population>The pharmacokinetic (PK) set included all participants from the safety set who received TAK-418 and had at least 1 measurable plasma concentration for TAK-418.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-418 1.5 mg</title>
            <description>TAK-418 1.5 mg, capsule, orally, once on Day 1 and up to 10 mCi of [18F]MNI-1054 PET radiotracer injection, intravenously, prior to each PET scans on Day 1, and either on Day 2 or 3 post-TAK-418 dose in the Treatment Period. All participants received [18F]MNI-1054 up to 10 mCi, injection, intravenously, prior to PET scan on Day -1 (Baseline scan).</description>
          </group>
          <group group_id="O2">
            <title>TAK-418 10 mg</title>
            <description>TAK-418 10 mg, capsule, orally, once on Day 1 and up to 10 mCi of [18F]MNI-1054 PET radiotracer injection, intravenously, prior to each PET scans on Day 1, and either on Day 2 or 3 post-TAK-418 dose in the Treatment Period. All participants received [18F]MNI-1054 up to 10 mCi, injection, intravenously, prior to PET scan on Day -1 (Baseline scan).</description>
          </group>
          <group group_id="O3">
            <title>TAK-418 30 mg</title>
            <description>TAK-418 30 mg, capsule, orally, once on Day 1 and up to 10 mCi of [18F]MNI-1054 PET radiotracer injection, intravenously, prior to each PET scans on Day 1, and either on Day 2 or 3 post-TAK-418 dose in the Treatment Period. All participants received [18F]MNI-1054 up to 10 mCi, injection, intravenously, prior to PET scan on Day -1 (Baseline scan).</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Maximum Observed Plasma Concentration for TAK-418</title>
          <population>The pharmacokinetic (PK) set included all participants from the safety set who received TAK-418 and had at least 1 measurable plasma concentration for TAK-418.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.420" lower_limit="4.23" upper_limit="4.61"/>
                    <measurement group_id="O2" value="43.80" lower_limit="36.7" upper_limit="50.9"/>
                    <measurement group_id="O3" value="130.5" lower_limit="127" upper_limit="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUClast: Area Under the Plasma Concentration-time Curve (AUC) From Time 0 to Time of the Last Quantifiable Concentration for TAK-418</title>
        <time_frame>Day 1: pre-dose and at multiple time points (up to 3 hours) post-dose, immediately before and after the Day 1 PET scan, and within 30 minutes before and 30 minutes after Day 2 or 3 PET scan</time_frame>
        <population>The PK set included all participants from the safety set who received TAK-418 and had at least 1 measurable plasma concentration for TAK-418.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-418 1.5 mg</title>
            <description>TAK-418 1.5 mg, capsule, orally, once on Day 1 and up to 10 mCi of [18F]MNI-1054 PET radiotracer injection, intravenously, prior to each PET scans on Day 1, and either on Day 2 or 3 post-TAK-418 dose in the Treatment Period. All participants received [18F]MNI-1054 up to 10 mCi, injection, intravenously, prior to PET scan on Day -1 (Baseline scan).</description>
          </group>
          <group group_id="O2">
            <title>TAK-418 10 mg</title>
            <description>TAK-418 10 mg, capsule, orally, once on Day 1 and up to 10 mCi of [18F]MNI-1054 PET radiotracer injection, intravenously, prior to each PET scans on Day 1, and either on Day 2 or 3 post-TAK-418 dose in the Treatment Period. All participants received [18F]MNI-1054 up to 10 mCi, injection, intravenously, prior to PET scan on Day -1 (Baseline scan).</description>
          </group>
          <group group_id="O3">
            <title>TAK-418 30 mg</title>
            <description>TAK-418 30 mg, capsule, orally, once on Day 1 and up to 10 mCi of [18F]MNI-1054 PET radiotracer injection, intravenously, prior to each PET scans on Day 1, and either on Day 2 or 3 post-TAK-418 dose in the Treatment Period. All participants received [18F]MNI-1054 up to 10 mCi, injection, intravenously, prior to PET scan on Day -1 (Baseline scan).</description>
          </group>
        </group_list>
        <measure>
          <title>AUClast: Area Under the Plasma Concentration-time Curve (AUC) From Time 0 to Time of the Last Quantifiable Concentration for TAK-418</title>
          <population>The PK set included all participants from the safety set who received TAK-418 and had at least 1 measurable plasma concentration for TAK-418.</population>
          <units>hour*nanogram per milliliter(h*ng/mL)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.40" lower_limit="20.8" upper_limit="24.0"/>
                    <measurement group_id="O2" value="227.5" lower_limit="223" upper_limit="232"/>
                    <measurement group_id="O3" value="812.0" lower_limit="718" upper_limit="906"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUCâˆž: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-418</title>
        <time_frame>Day 1: pre-dose and at multiple time points (up to 3 hours) post-dose, immediately before and after the Day 1 PET scan, and within 30 minutes before and 30 minutes after Day 2 or 3 PET scan</time_frame>
        <population>The PK set included all participants from the safety set who received TAK-418 and had at least 1 measurable plasma concentration for TAK-418. Here &quot;overall number of participants&quot; analyzed are those who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-418 1.5 mg</title>
            <description>TAK-418 1.5 mg, capsule, orally, once on Day 1 and up to 10 mCi of [18F]MNI-1054 PET radiotracer injection, intravenously, prior to each PET scans on Day 1, and either on Day 2 or 3 post-TAK-418 dose in the Treatment Period. All participants received [18F]MNI-1054 up to 10 mCi, injection, intravenously, prior to PET scan on Day -1 (Baseline scan).</description>
          </group>
          <group group_id="O2">
            <title>TAK-418 10 mg</title>
            <description>TAK-418 10 mg, capsule, orally, once on Day 1 and up to 10 mCi of [18F]MNI-1054 PET radiotracer injection, intravenously, prior to each PET scans on Day 1, and either on Day 2 or 3 post-TAK-418 dose in the Treatment Period. All participants received [18F]MNI-1054 up to 10 mCi, injection, intravenously, prior to PET scan on Day -1 (Baseline scan).</description>
          </group>
          <group group_id="O3">
            <title>TAK-418 30 mg</title>
            <description>TAK-418 30 mg, capsule, orally, once on Day 1 and up to 10 mCi of [18F]MNI-1054 PET radiotracer injection, intravenously, prior to each PET scans on Day 1, and either on Day 2 or 3 post-TAK-418 dose in the Treatment Period. All participants received [18F]MNI-1054 up to 10 mCi, injection, intravenously, prior to PET scan on Day -1 (Baseline scan).</description>
          </group>
        </group_list>
        <measure>
          <title>AUCâˆž: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-418</title>
          <population>The PK set included all participants from the safety set who received TAK-418 and had at least 1 measurable plasma concentration for TAK-418. Here &quot;overall number of participants&quot; analyzed are those who were evaluable for this outcome measure.</population>
          <units>h*ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.60" lower_limit="25.6" upper_limit="25.6"/>
                    <measurement group_id="O2" value="230.0" lower_limit="225" upper_limit="235"/>
                    <measurement group_id="O3" value="817.0" lower_limit="721" upper_limit="913"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ED50 PET Enzyme Occupancy</title>
        <description>The relationship between PET enzyme occupancy and TAK-418 dose level was investigated using an Emax model containing the regression parameters maximal target occupancy (Emax) and dose that gives 50 percent (%) of Emax (ED50). ED50 values are reported for following brain regions: cerebellum, frontal lobe, hippocampus, occipital Lobe, pons, and striatum. The data tabulated are the estimated value and confidence intervals of the ED50 value derived from an Emax model fit across all data points from all arms. ED50 is the dose at which 50% enzyme occupancy is expected.</description>
        <time_frame>Days 1 to 2</time_frame>
        <population>The PD set included all participants who received TAK-418 and have at least 1 analyzable PET Scan following TAK-418</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-418</title>
            <description>TAK-418 1.5 mg, 10 mg, or 30 mg capsules, orally, once on Day 1 and up to 10 mCi of [18F]MNI-1054 PET radiotracer injection, intravenously, prior to each PET scans on Day 1, and either on Day 2 or 3 post-TAK-418 dose. All participants received [18F]MNI-1054 up to 10 mCi, injection, intravenously, prior to PET scan on Day -1 (Baseline scan).</description>
          </group>
        </group_list>
        <measure>
          <title>ED50 PET Enzyme Occupancy</title>
          <description>The relationship between PET enzyme occupancy and TAK-418 dose level was investigated using an Emax model containing the regression parameters maximal target occupancy (Emax) and dose that gives 50 percent (%) of Emax (ED50). ED50 values are reported for following brain regions: cerebellum, frontal lobe, hippocampus, occipital Lobe, pons, and striatum. The data tabulated are the estimated value and confidence intervals of the ED50 value derived from an Emax model fit across all data points from all arms. ED50 is the dose at which 50% enzyme occupancy is expected.</description>
          <population>The PD set included all participants who received TAK-418 and have at least 1 analyzable PET Scan following TAK-418</population>
          <units>milligram (mg)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cerebellum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.756" lower_limit="0.288" upper_limit="1.224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Frontal Lobe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.328" lower_limit="0.129" upper_limit="8.527"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hippocampus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.639" lower_limit="-0.098" upper_limit="3.377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occipital Lobe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.416" lower_limit="0.141" upper_limit="2.690"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pons</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.112" lower_limit="-0.976" upper_limit="3.200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Striatum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.496" lower_limit="-2.050" upper_limit="17.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting One or More Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
        <time_frame>From first dose of [18F]MNI-1054 radiotracer injection up to Day 14</time_frame>
        <population>The safety set included all enrolled participants who received at least 1 dose of [18F]MNI-1054 or TAK-418</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline [18F]MNI-1054</title>
            <description>[18F]MNI-1054 up to 10 mCi, PET radiotracer injection, intravenously, prior to PET scan on Day -1 (Baseline scan).</description>
          </group>
          <group group_id="O2">
            <title>TAK-418 1.5 mg</title>
            <description>TAK-418 1.5 mg, capsule, orally, once on Day 1 and up to 10 mCi of [18F]MNI-1054 PET radiotracer injection, intravenously, prior to each PET scans on Day 1, and either on Day 2 or 3 post-TAK-418 dose in the Treatment Period. All participants received [18F]MNI-1054 up to 10 mCi, injection, intravenously, prior to PET scan on Day -1 (Baseline scan).</description>
          </group>
          <group group_id="O3">
            <title>TAK-418 10 mg</title>
            <description>TAK-418 10 mg, capsule, orally, once on Day 1 and up to 10 mCi of [18F]MNI-1054 PET radiotracer injection, intravenously, prior to each PET scans on Day 1, and either on Day 2 or 3 post-TAK-418 dose in the Treatment Period. All participants received [18F]MNI-1054 up to 10 mCi, injection, intravenously, prior to PET scan on Day -1 (Baseline scan).</description>
          </group>
          <group group_id="O4">
            <title>TAK-418 30 mg</title>
            <description>TAK-418 30 mg, capsule, orally, once on Day 1 and up to 10 mCi of [18F]MNI-1054 PET radiotracer injection, intravenously, prior to each PET scans on Day 1, and either on Day 2 or 3 post-TAK-418 dose in the Treatment Period. All participants received [18F]MNI-1054 up to 10 mCi, injection, intravenously, prior to PET scan on Day -1 (Baseline scan).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting One or More Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
          <population>The safety set included all enrolled participants who received at least 1 dose of [18F]MNI-1054 or TAK-418</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Abnormal Laboratory Values</title>
        <time_frame>From first dose of [18F]MNI-1054 radiotracer injection up to Day 14</time_frame>
        <population>The safety set included all enrolled participants who received at least 1 dose of [18F]MNI-1054 or TAK-418</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline [18F]MNI-1054</title>
            <description>[18F]MNI-1054 up to 10 mCi, PET radiotracer injection, intravenously, prior to PET scan on Day -1 (Baseline scan).</description>
          </group>
          <group group_id="O2">
            <title>TAK-418 1.5 mg</title>
            <description>TAK-418 1.5 mg, capsule, orally, once on Day 1 and up to 10 mCi of [18F]MNI-1054 PET radiotracer injection, intravenously, prior to each PET scans on Day 1, and either on Day 2 or 3 post-TAK-418 dose in the Treatment Period. All participants received [18F]MNI-1054 up to 10 mCi, injection, intravenously, prior to PET scan on Day -1 (Baseline scan).</description>
          </group>
          <group group_id="O3">
            <title>TAK-418 10 mg</title>
            <description>TAK-418 10 mg, capsule, orally, once on Day 1 and up to 10 mCi of [18F]MNI-1054 PET radiotracer injection, intravenously, prior to each PET scans on Day 1, and either on Day 2 or 3 post-TAK-418 dose in the Treatment Period. All participants received [18F]MNI-1054 up to 10 mCi, injection, intravenously, prior to PET scan on Day -1 (Baseline scan).</description>
          </group>
          <group group_id="O4">
            <title>TAK-418 30 mg</title>
            <description>TAK-418 30 mg, capsule, orally, once on Day 1 and up to 10 mCi of [18F]MNI-1054 PET radiotracer injection, intravenously, prior to each PET scans on Day 1, and either on Day 2 or 3 post-TAK-418 dose in the Treatment Period. All participants received [18F]MNI-1054 up to 10 mCi, injection, intravenously, prior to PET scan on Day -1 (Baseline scan).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Abnormal Laboratory Values</title>
          <population>The safety set included all enrolled participants who received at least 1 dose of [18F]MNI-1054 or TAK-418</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Abnormal Vital Signs</title>
        <time_frame>From first dose of [18F]MNI-1054 radiotracer injection up to Day 14</time_frame>
        <population>The safety set included all enrolled participants who received at least 1 dose of [18F]MNI-1054 or TAK-418.</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline [18F]MNI-1054</title>
            <description>[18F]MNI-1054 up to 10 mCi, PET radiotracer injection, intravenously, prior to PET scan on Day -1 (Baseline scan).</description>
          </group>
          <group group_id="O2">
            <title>TAK-418 1.5 mg</title>
            <description>TAK-418 1.5 mg, capsule, orally, once on Day 1 and up to 10 mCi of [18F]MNI-1054 PET radiotracer injection, intravenously, prior to each PET scans on Day 1, and either on Day 2 or 3 post-TAK-418 dose in the Treatment Period. All participants received [18F]MNI-1054 up to 10 mCi, injection, intravenously, prior to PET scan on Day -1 (Baseline scan).</description>
          </group>
          <group group_id="O3">
            <title>TAK-418 10 mg</title>
            <description>TAK-418 10 mg, capsule, orally, once on Day 1 and up to 10 mCi of [18F]MNI-1054 PET radiotracer injection, intravenously, prior to each PET scans on Day 1, and either on Day 2 or 3 post-TAK-418 dose in the Treatment Period. All participants received [18F]MNI-1054 up to 10 mCi, injection, intravenously, prior to PET scan on Day -1 (Baseline scan).</description>
          </group>
          <group group_id="O4">
            <title>TAK-418 30 mg</title>
            <description>TAK-418 30 mg, capsule, orally, once on Day 1 and up to 10 mCi of [18F]MNI-1054 PET radiotracer injection, intravenously, prior to each PET scans on Day 1, and either on Day 2 or 3 post-TAK-418 dose in the Treatment Period. All participants received [18F]MNI-1054 up to 10 mCi, injection, intravenously, prior to PET scan on Day -1 (Baseline scan).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Abnormal Vital Signs</title>
          <population>The safety set included all enrolled participants who received at least 1 dose of [18F]MNI-1054 or TAK-418.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse events are adverse events that started after the first administration of [18F]MNI-1054 radiotracer injection until the Day 14</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Baseline [18F]MNI-1054</title>
          <description>[18F]MNI-1054 up to 10 mCi, PET radiotracer injection, intravenously, prior to PET scan on Day -1 (Baseline scan).</description>
        </group>
        <group group_id="E2">
          <title>TAK-418 1.5 mg</title>
          <description>TAK-418 1.5 mg, capsule, orally, once on Day 1 and up to 10 mCi of [18F]MNI-1054 PET radiotracer injection, intravenously, prior to each PET scans on Day 1, and either on Day 2 or 3 post-TAK-418 dose in the Treatment Period. All participants received [18F]MNI-1054 up to 10 mCi, injection, intravenously, prior to PET scan on Day -1 (Baseline scan).</description>
        </group>
        <group group_id="E3">
          <title>TAK-418 10 mg</title>
          <description>TAK-418 10 mg, capsule, orally, once on Day 1 and up to 10 mCi of [18F]MNI-1054 PET radiotracer injection, intravenously, prior to each PET scans on Day 1, and either on Day 2 or 3 post-TAK-418 dose in the Treatment Period. All participants received [18F]MNI-1054 up to 10 mCi, injection, intravenously, prior to PET scan on Day -1 (Baseline scan).</description>
        </group>
        <group group_id="E4">
          <title>TAK-418 30 mg</title>
          <description>TAK-418 30 mg, capsule, orally, once on Day 1 and up to 10 mCi of [18F]MNI-1054 PET radiotracer injection, intravenously, prior to each PET scans on Day 1, and either on Day 2 or 3 post-TAK-418 dose in the Treatment Period. All participants received [18F]MNI-1054 up to 10 mCi, injection, intravenously, prior to PET scan on Day -1 (Baseline scan).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

